C5b-9 terminal complement complex protects oligodendrocytes from death by regulating bad through phosphatidylinositol 3-kinase/Akt pathway

Journal of Immunology

Volumn 167, Issue 4, 2001, Pages 2305-2311

  Soane, L ^a   Cho, H J ^a   Niculescu, F ^a   Rus, H ^a   Shin, M L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CASPASE 9; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOCHROME C; GROWTH FACTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATING DISEASE; ENZYME ACTIVITY; INFLAMMATORY DISEASE; MITOCHONDRION; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; STEM CELL;

EID: 0035881950     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.4.2305     Document Type: Article

References (59)

1. Cell death and control of cell survival in the oligodendrocyte lineage
2. Programmed cell death and the control of cell survival: Lessons from the nervous system
3. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain
4. Lack of replicating senescence in cultured rat oligodendrocyte precursor cells
5. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons
6. Cell death and birth in multiple sclerosis brain
7. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis
8. Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease
9. Immunologic aspects of demyelinating diseases
10. The Norton lecture: A review of the oligodendrocyte in the multiple sclerosis lesion
11. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75
12. Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions
13. Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis
14. Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis
15. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex
16. Immunocytochemical localization of terminal complement complex in multiple sclerosis
17. Complement activation by β-amyloid in Alzheimer disease
18. Activation of the classical complement pathway in brain tissue of Alzheimer patients
19. Complement activation in the central nervous system following blood-brain barrier damage in man
20. Lewy bodies in Parkinson's disease are recongnized by antibodies to complement proteins
21. Membrane attack by complement: Assembly and biology of terminal complement complexes
22. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9
23. Transgenic pigs expressing human CD59 and decay accelerating factor produce an intrinsic barrier to complement-mediated damage
24. Complement regulatory molecules on human myelin and glial cells: Differential expression affects the deposition of activated complement proteins
25. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in human astroglioma cell line, D54-MG, and primary rat astrocytes
26. Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack
27. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: The rate of disappearance differs for cells carrying C5b-7 or C5b-8, or a mixture of C5b-8 with a limited number of C5b-9
28. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement
29. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of caspase-3 activation
30. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent
31. Sublytic complement attack induces cell cycle in oligodendrocytes
32. Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway
33. Sublytic C5b-9 induces proliferation of aortic smooth muscle cells: Role of mitogen activated protein kinase and phosphatidylinositol 3-kinase
34. Pi3k: Downstream AKTion blocks apoptosis
35. Oligodendrocytes and their precursors require phosphatidyl-inositol-3-kinase signaling for survival
36. Linking extracellular survival signals and the apoptotic machinery
37. Survival function of ERK1/2 as IL-3 activated, staurosporine-resistant Bcl-2 kinases
38. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and independent mechanisms
39. Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery
40. Cellular survival: A play in three Akts
41. Bcl-2 family members and the mitochondria in apoptosis
42. L and proapoptotic activity
43. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not Bcl-X(L)
44. Characterization of cultured rat oligodendrocytes proliferating in a serum-free chemically defined medium
45. The activation of human complement component C5 by a fluid phase C5 convertase
46. Assays for Akt
47. The cytoskeleton of digitonin-treated rat hepatocytes
48. m) and cytochrome c release are caspase independent
49. Preservation of mitochondrial structure and function after Bid- or Bax-mediated cytochrome c release
50. Mitochondria and apoptosis
51. Nerve growth factor protects oligodendrocytes from tumor necrosis factor-α-induced injury through Akt-mediated signaling mechanisms
52. Conditional inhibition of the mitogen-activated protein kinase by wortmannin: Dependence on signal strength
53. Regulation of Bad phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway
54. 155
55. 155
56. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival
57. Phosphorylation and inactivation of Bad by mitochondria-anchored protein kinase A
58. BH3-only proteins essential initiators of apoptotic cell death
59. Multiple sclerosis: In situ evidence for antibody and complement mediated demyelination